AcSé-ESMART
Therapy study based on targeting molecular changes in refractory or recurrent tumours
This study investigates whether the treatment of patients with recurrent or refractory (treatment-resistant) tumours can be improved through molecular analysis and subsequent stratification. Stratification here means assigning patients to targeted therapy based on specific mutations identified in the molecular analysis. Patients who meet the criteria for participation in the study are assigned to one of the study arms (also known as groups) based on the results of the molecular analysis of their tumour/leukaemia cells. Different drugs are used in a targeted manner in the various study arms.
Is this study suitable for my child’s condition?
Leukaemia, lymphoma and bone marrow disease
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Myelodysplastic syndrome (MDS)
- Severe aplastic anemia (SAA)
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Other leukaemia, lymphoma and bone marrow disease
Brain and spinal cord tumors
- Low-grade glioma
- High-grade glioma
- Diffuse-intrinsic pontine glioma (DIPG) / Diffuse midline glioma (DMG)
- Medulloblastoma
- Atypical teratoid rhabdoid tumours (ATRT)
- Ependymoma
- Germ cell tumours / germinoma / nongerminomatous germ cell tumours / teratoma (brain / spinal cord)
- Craniopharyngioma
- Other brain tumours or spinal cord tumours
Solid tumors
- Wilms tumours / nephroblastoma
- Neuroblastoma
- Rhabdomyosarcoma
- Ewing sarcoma
- Osteosarcoma
- Rhabdoid tumours (other than brain or spinal cord)
- Other sarcoma
- Germ cell tumours (other than brain or spinal cord)
- Retinoblastoma
- Hepatoblastoma
- Other solid tumours
Study Information
What age range of children can participate?
Up to 18 years
Official Study Information
Study at www.humanforschung-schweiz.ch
Study at www.clinicaltrials.gov
Questions? Please contact your medical team.
If you would like more information about a study, please speak to your child’s treating physician. They are your primary point of contact and can provide personalized advice and support. If no treatment team is currently in place, you can find general contact information for the study sites on the map below.
Treatment Centers with Open Study – Map & Overview
The map shows all treatment sites in Switzerland. Locations where the study is currently open are marked in blue. You can find contact details by clicking on the towns. The information on study sites is updated regularly. However, a study may occasionally open at a new site before this is reflected on the platform. If in doubt, please contact your treatment team or one of the listed clinics directly.
Lausanne
CHUV Centre Hospitalier Universitaire Vaudois
Service de pédiatrie – Département femme-mère-enfant
Hôpital des Enfants CHUV
Rue du Bugnon 50
1011 Lausanne
https://www.chuv.ch
Unité d’hématologie-oncologie pédiatrique (HOP)
Main phone : +41 21 314 35 90
Email: ped.pon@chuv.ch
https://www.chuv.ch/fr/dfme/dfme-home/enfants-famille/specialites-medicales/hematologie-oncologie-pediatrique/oncologie-pediatrique
Zürich
Universitäts-Kinderspital Zürich –
Eleonorenstiftung
Lenggstrasse 30
8008 Zürich
https://www.kispi.uzh.ch
Sekretariat Onkologie
Telefon: +41 44 249 63 50
E-Mail: onkologie.sekretariat@kispi.uzh.ch